PKU Medicine Teams Lead the Winning of Four of the 2022 Chinese Medical Science and Technology Awards
On March 24, 2023, the Chinese Medical Association issued the decision on granting the 2022 Chinese Medical Science and Technology Award. Research teams from PKU Medicine led the winning of four prizes, including one first prize, two second prizes, and one third prize, which marked another harvest in this important science and technology award of the national medical and health industry.
First prize winning project: The key technology and clinical application of large bone and joint defect repair and reconstruction after bone tumor resection
First Accomplisher: Guo Wei, Peking University People’s Hospital
To solve the worldwide problem of repair and reconstruction of large bone and joint defects after bone tumor resection, through concept innovation and patent transformation, application of key technologies such as modular design and additive manufacturing, the research group has greatly improved the prognosis and limb salvage function of patients with malignant bone tumors in China and the results have reached the international leading level.
Second prize winning project: Study on the neural mechanism and intervention of addiction and related mental diseases
First Accomplisher: Shi Jie, National Institute on Drug Dependence, Peking University
By applying neuropharmacology, molecular biology, and medical psychology, the project team systematically studied the core pathological mechanisms, risk factors and intervention methods of addiction and related mental diseases. The team proposed the non-pharmacological and pharmacological intervention methods for eliminating pathological memory such as addiction after non-conditional stimulus arousal, clarified the key molecular and cellular mechanisms of dynamic updating of pathological addiction memory, explained the neuron cluster map of non-conditional stimulus arousal activation of addiction memory, clarified the common genetic risk loci of multiple substance addictions, and found the key factors to reduce addiction-related mortality.
Second prize winning project: Development of a new psoriasis drug aromatic hydrocarbon receptor modulator
First Accomplisher: Zhang Jianzhong, Peking University People’s Hospital
Psoriasis is a chronic, recurrent, and inflammatory skin disease that is currently incurable and requires long-term treatment. In this study, the first-in-class new drug benvitimod was successfully developed for the first time in the world through collaborative research. In May 2019, benvitimod cream was approved by the National Medical Products Administration for marketing in our country, which marks a breakthrough in the field of international psoriasis external drug research in the past 40 years.
Third prize winning project: Recurrence mechanism and tr4eatment strategy of liver tumor after radiofrequency ablation
First Accomplisher: Yang Wei, Peking University Cancer Hospital
For more than ten years, Professor Yang Wei’s team has been exploring the specific reactions and changes of tumor tissue and microenvironment after RFA and has created new combined treatment strategies and solved the technical problems of RFA in the treatment of liver tumors with rich blood supply and special sites, which has helped reduce the recurrence after treatment, broken through the RFA treatment bottleneck, and achieved remarkable clinical effect.
Written by: Lang Lang
Edited by: Liu Xin
Source: Office of Scientific Research